Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.

Détails

Ressource 1Télécharger: 33312857_BIB_D07C5F1D118C.pdf (3440.70 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_D07C5F1D118C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.
Périodique
Respiratory medicine case reports
Auteur⸱e⸱s
Daccord C., Nicolas A., Demicheli R., Chehade H., Hottinger A.F., Beigelman C., Lazor R.
ISSN
2213-0071 (Print)
ISSN-L
2213-0071
Statut éditorial
Publié
Date de publication
2020
Peer-reviewed
Oui
Volume
31
Pages
101310
Langue
anglais
Notes
Publication types: Case Reports
Publication Status: epublish
Résumé
Multifocal micronodular pneumocyte hyperplasia (MMPH) is a benign proliferation of alveolar type II cells presenting as multiple pulmonary nodules at chest imaging, which is frequently seen in patients with tuberous sclerosis complex (TSC). We report a case of a woman with TSC and MMPH who received everolimus, a mechanistic target of rapamycin (mTOR) inhibitor, for the treatment of a subependymal giant cell astrocytoma (SEGA). After 3 months of therapy, a remarkable decrease in density of all pulmonary MMPH lesions was observed, without any change in size. This shows that everolimus is active on MMPH similarly to its effects on SEGA, renal angiomyolipomas, and pulmonary lymphangioleiomyomatosis in TSC, and suggests that the dysregulated activation of mTOR which characterizes TSC also plays a role in the pathogenesis of MMPH.
Mots-clé
Alveolar epithelial cells, Everolimus, Lung, Mechanistic target of rapamycin, Multifocal micronodular pneumocyte hyperplasia, Tuberous sclerosis
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/12/2020 10:33
Dernière modification de la notice
30/04/2021 7:15
Données d'usage